WindMIL Therapeutics
Princeton
About WindMIL Therapeutics
WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $42.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2018)
- Website: windmiltx.com
- Phone: 410-558-1906
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/windmil-therapeutics-69080 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.